News Archive

Maryland Governor Larry Hogan visited United Therapeutics headquarters in Silver Spring on Thursday afternoon.

He was joined by Montgomery County Council President Nancy Floreen and Council member Tom Hucker.

QIAGEN N.V. today announced introduction of its unique RNA-seq Explorer Solution, a bioinformatics-driven approach to analysis and interpretation of “omics” data from liquid biopsy-based research. RNA-seq Explorer Solution is a new tool which integrates Ingenuity® Pathway Analysis™, Biomedical Genomics Workbench® and other QIAGEN bioinformatics solutions to generate clear insights for research into improved detection, diagnosis and treatment of cancer. The solution will be demonstrated at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans.

Montgomery County Department of Economic Development has played an active role in the cultivation of new and innovative technologies developed in federal laboratories and academia, known as technology transfer.

Chris Vizas, Chairman of SmartSenseCom, Inc., wraps up DED’s Tech Transfer Speakers Series The term “technology transfer” entered the public lexicon in 1986 through the Technology Transfer Act. This vehicle gave promise to millions of scientists and entrepreneurs who wanted to work with these innovative and sometimes disruptive technologies to commercialize them and bring them to the marketplace.

Cydan Development, Inc. raised $31 million in Series A funding from New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. Cydan raised the capital to launch Imara, Inc., which is developing treatment for sickle cell disease.

The Tom Tom Founders Festival held a Youth Summit at the Paramount Theater Thursday to support and highlight local student innovation.

The summit featured student-led presentations and several student entrepreneurial competitions. Wes Bellamy, vice-mayor of Charlottesville, gave the keynote address, and Virginia Gov. Terry McAuliffe signed a bill to protect the rights of student innovators.

Baltimore-area companies accounted for eight of the 10 biggest venture capital deals in the state during the first quarter of 2016.

Maryland companies raised a total of $109.8 million in 19 deals during the first quarter, up from $97 million invested in 14 deals the same quarter last year, according to a MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association, based on data from Thomson Reuters. The amount invested in Maryland is up 13 percent and the number of deals is up 36 percent, compared to the year-ago quarter.

Maryland legislators recently approved a $42.3 billion fiscal year 2017 spending bill that incorporates many of the funding levels included in Gov. Larry Hogan’s proposal. Gov. Hogan made education a main focus of his proposal, and the final bill would hold university tuition increases to no more than 2 percent. In addition, legislators formalized the growing strategic partnership between University of Maryland campuses in Baltimore and College Park. The unification is intended to bolster the state’s research profile, and drive high-tech industries in the Baltimore region.

Much has been made of China’s efforts to close the gap between western high technology sectors, and in the case of certain spaces, to actually bridge the gap and become a global leader.  In form, these efforts represent the potential – but not the inevitability – of similar outcomes in other high technology sectors.  One of the sectors that has received significant interest by the Chinese government are life sciences; however, as we found in a nearly two year survey of various Chinese officials, entrepreneurs and multinationals, the unique requirements to re-create the innovative ecosystem for the life science space remain immature in China.  While the potential for China to disrupt how and where life science innovation takes place globally, there are reasons to believe the country’s policies to develop domestic success stories may fall short of similar endeavors in other high technology segments such as clean-technology.

Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s lead product, Epi proColon® , the first and only FDA-approved blood-based colorectal cancer screening test.

May 23-25, 2016 – Washington, DC

SBIR/STTR programs are the nation’s largest source of early stage / high risk R&D funding for small business. At this conference you’ll learn how to participate and compete for funding in these two programs that encourage small businesses to engage in Federal Research/Research and Development (R/R&D) and to commercialize your technological innovations.